|Articles|July 1, 2018
- Pharmaceutical Executive-07-01-2018
- Volume 38
- Issue 7
Pharmaceutical Executive, July 2018 Issue (PDF)
Click the title above to open the Pharmaceutical Executive July 2018 issue in an interactive PDF format.
Advertisement
Articles in this issue
about 7 years ago
Opioid Litigation: Evading the Widening Crosshairsabout 7 years ago
Patient & Customer-Centric Commercializationover 7 years ago
Compliance: The Critical Cog in Pharma Machineover 7 years ago
Gaining Ground with Stem Cells: Gil Van Bokkelen, Athersysover 7 years ago
A Seat at the Strategy Tableover 7 years ago
Regulatory Innovation Generates Breakthroughsover 7 years ago
China’s Biopharma Rise: Opportunities and ThreatsNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Novo Nordisk Enters $4.7 Billion Definitive Agreement with Akero Therapeutics
2
FDA Approves Libtayo for Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma
3
Most Favored Nation Order: Legal Battles, Market Shifts, and the Future of Drug Pricing Reform
4
The Situation We Faced: The Development and Commercialization of MariTide
5
